News from tarsa therapeutics

May 29, 2014, 07:00 ET

Tarsa Therapeutics Raises $7 Million To Prepare For Filing NDA For Ostora, Its Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis

 Tarsa Therapeutics, Inc. today announced that it raised $7 million to prepare for filing a New Drug Application (NDA) with the U.S. Food and...

Oct 07, 2013, 07:00 ET

Tarsa Therapeutics Presents Meta-Analysis At ASBMR 2013 Showing Calcitonin Does Not Appear To Be Associated With Increased Risk Of Cancer

 Tarsa Therapeutics, Inc. today announced that it presented a new meta-analysis showing that salmon calcitonin does not appear to be associated...

Oct 16, 2012, 07:30 ET

Tarsa Therapeutics Reports Positive Results From Phase II Trial Of Its Oral Calcitonin In Prevention Of Post-Menopausal Osteoporosis

 Tarsa Therapeutics, Inc. today announced that a Phase II trial of its oral recombinant salmon calcitonin in the prevention of postmenopausal...

Oct 12, 2012, 08:00 ET

Tarsa Therapeutics To Assist Therapicon In Its Challenge To CHMP's Recommendation To Limit Use Of Calcitonin

 Tarsa Therapeutics today announced an agreement in principle with Therapicon® Slr to provide consulting assistance to the Italian firm in...

Mar 21, 2012, 07:30 ET

Tarsa Therapeutics Signs Commercial Supply Agreement for its Ostora™ Oral Calcitonin Product With QS Pharma

Tarsa Therapeutics today announced it has entered into a commercial supply agreement with QS Pharma for the bulk manufacture of its OSTORA™...

Mar 16, 2012, 07:30 ET

Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin

 Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital. ...

Dec 13, 2011, 08:00 ET

Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin

Tarsa Therapeutics today confirmed that it is planning to submit a New Drug Application (NDA) to the Food and Drug Administration (FDA) in the...

Sep 19, 2011, 07:00 ET

Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial

Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA™, the...

Jul 12, 2011, 07:30 ET

Tarsa Therapeutics Advances Its Oral Calcitonin for the Treatment and Prevention of Postmenopausal Osteoporosis

Tarsa Therapeutics today reported progress in its two ongoing  clinical development programs for its oral recombinant salmon calcitonin for...

Mar 24, 2011, 07:30 ET

Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis

Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of postmenopausal...

Feb 14, 2011, 07:30 ET

Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention

Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant...

Sep 24, 2010, 09:30 ET

Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis

Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. (OTC Bulletin Board: UGNE) today reported preclinical data showing that calcitonin may have...

Jul 22, 2010, 07:00 ET

Tarsa Therapeutics Advances Phase III ORACAL Trial of its Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis

Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal...

Feb 18, 2010, 08:00 ET

Tarsa Therapeutics Announces Addition of Senior Level Clinical and Regulatory Expertise

Tarsa Therapeutics, Inc. today announced the addition of two executives to its senior management team. David Krause, M.D., F.A.C.P., has joined as...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer